Market Capitalization (Millions $) |
23 |
Shares
Outstanding (Millions) |
5 |
Employees |
- |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-12 |
Cash Flow (TTM) (Millions $) |
19 |
Capital Exp. (TTM) (Millions $) |
0 |
Neurobo Pharmaceuticals Inc
Neurobo Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that focuses on the development of novel therapies for the treatment of neurological and neuromuscular diseases. The company is dedicated to addressing unmet medical needs and improving the lives of patients suffering from debilitating conditions. Neurobo Pharmaceuticals is known for its research and development efforts in neurology, where it aims to discover and develop innovative drugs that can potentially provide therapeutic benefits to patients. The company's pipeline includes candidates for conditions such as diabetic neuropathy, Alzheimer's disease, and neurodegenerative disorders. Neurobo Pharmaceuticals is committed to advancing its drug candidates through clinical trials and regulatory processes to ultimately deliver effective treatments to patients in need.
Company Address: 545 Concord Avenue, Suite 210 Cambridge, 2138 MA
Company Phone Number: 702-9600 Stock Exchange / Ticker: NASDAQ NRBO
NRBO is expected to report next financial results on March 29, 2024. |
|
|